Joeky Senders

81 Thromboprophylaxis after craniotomy Reference 1. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404-1413. 2. Constantini S, Kornowski R, Pomeranz S, Rappaport ZH. Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. Acta neurochirurgica. 1991;109(3-4):93- 97. 3. Chaichana KL, Pendleton C, Jackson C, et al. Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. Neurological research. 2013;35(2):206-211. 4. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high- grade gliomas: a prospective study. Eur J Cancer. 1997;33(10):1592-1596. 5. Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 2004;100(8):1717-1723. 6. Smith TR, Lall RR, Graham RB, et al. Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period. Journal of neuro-oncology. 2014;120(2):347- 352. 7. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high- grade glioma. Neuro Oncol. 2007;9(2):89-95. 8. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. Journal of neurosurgery. 2007;106(4):601-608. 9. Robins HI, O'Neill A, Gilbert M, et al. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol. 2008;62(2):227- 233. 10. Perry SL, Bohlin C, ReardonDA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. Journal of neuro-oncology. 2009;95(1):129-134. 11. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. Journal of thrombosis and haemostasis : JTH. 2010;8(9):1959-1965. 12. Pan E, Tsai JS, Mitchell SB. Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer research. 2009;29(10):4309-4313. 13. EdwinNC, KhouryMN, Sohal D,McCraeKR, AhluwaliaMS, KhoranaAA. Recurrent venous thromboembolism in glioblastoma. Thrombosis research. 2016;137:184-188. 14. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer. 1991;68(12):2621-2624. 15. Yust-Katz S, Mandel JJ, Wu J, et al. Venous thromboembolism (VTE) and glioblastoma. Journal of neuro- oncology. 2015;124(1):87-94. 16. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Annals of neurology. 1983;13(3):334-336. 17. Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O'Fallon JR. Thromboembolism in patients with high- grade glioma. Mayo Clinic proceedings. 1994;69(4):329-332. 18. Dhami MS, Bona RD, Calogero JA, Hellman RM. Venous thromboembolism and high grade gliomas. Thrombosis and haemostasis. 1993;70(3):393-396. 19. Streiff MB, Ye X, Kickler TS, et al. A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. Journal of neuro-oncology. 2015;124(2):299-305.